title: Clopidogrel: a case for indication-specific pharmacogenetics.
abstract: The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.
authors.affiliation: College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA. Johnson@cop.ufl.edu
authors.forename: J A
authors.initials: JA
authors.lastname: Johnson
authors.forename: D M
authors.initials: DM
authors.lastname: Roden
authors.forename: L J
authors.initials: LJ
authors.lastname: Lesko
authors.forename: E
authors.initials: E
authors.lastname: Ashley
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.forename: A R
authors.initials: AR
authors.lastname: Shuldiner
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine